Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15936MR)

This product GTTS-WQ15936MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15936MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5860MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ13053MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ1996MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ1952MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ9997MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ13385MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ13675MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ1718MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW